On June 24, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living wi……
On June 23, 2025, Nuvation Bio Inc. (NYSE: NUVB) announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic RO……
May 28, 2025 -- Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, for the treatment of the signs and symptoms of dry eye disease (DED). Tryptyr is a first - in - class TRPM8 recep……
May 22, 2025 -- U.S. President Donald Trump on Monday signed a sweeping executive order promising to target "unreasonable or discriminatory" practices by foreign countries that result in Americans paying more for prescri……
April 22, 2025 -- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adults and adolescents aged 22 years and old……
April 26, 2025 -- Eisai Co., Ltd. (“Eisai”) and Biogen Inc. (“Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi® (lecanemab) Marketing Authorization ……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
